Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 12 04:00PM ET
0.7900
Dollar change
-0.0010
Percentage change
-0.13
%
Index- P/E- EPS (ttm)-3.06 Insider Own2.19% Shs Outstand6.67M Perf Week4.53%
Market Cap5.27M Forward P/E- EPS next Y-0.13 Insider Trans0.00% Shs Float6.52M Perf Month0.39%
Income-13.97M PEG- EPS next Q-0.25 Inst Own3.03% Short Float2.23% Perf Quarter-12.22%
Sales1.38M P/S3.82 EPS this Y40.23% Inst Trans-36.12% Short Ratio1.37 Perf Half Y-37.30%
Book/sh0.29 P/B2.68 EPS next Y93.75% ROA-102.54% Short Interest0.15M Perf Year-73.31%
Cash/sh0.46 P/C1.71 EPS next 5Y- ROE-193.25% 52W Range0.55 - 3.76 Perf YTD-75.99%
Dividend Est.- P/FCF- EPS past 5Y53.33% ROI-380.51% 52W High-78.99% Beta1.21
Dividend TTM- Quick Ratio1.06 Sales past 5Y5.27% Gross Margin5.00% 52W Low43.64% ATR (14)0.07
Dividend Ex-Date- Current Ratio1.20 EPS Y/Y TTM34.05% Oper. Margin-960.49% RSI (14)53.00 Volatility8.34% 10.60%
Employees34 Debt/Eq1.22 Sales Y/Y TTM-23.75% Profit Margin-1013.00% Recom3.00 Target Price3.00
Option/ShortNo / Yes LT Debt/Eq0.86 EPS Q/Q38.35% Payout- Rel Volume0.50 Prev Close0.79
Sales Surprise-30.86% EPS Surprise-50.00% Sales Q/Q-51.66% EarningsNov 13 BMO Avg Volume105.87K Price0.79
SMA204.59% SMA509.54% SMA200-38.02% Trades Volume53,391 Change-0.13%
Date Action Analyst Rating Change Price Target Change
Aug-19-24Initiated H.C. Wainwright Buy $3
Dec-03-24 07:00AM
Nov-13-24 07:00AM
Oct-09-24 06:23PM
Sep-05-24 08:00AM
Aug-27-24 08:00AM
07:00AM Loading…
Aug-14-24 07:00AM
Aug-13-24 10:52PM
07:00AM
Aug-07-24 07:00AM
Jul-26-24 08:00AM
Jul-25-24 07:00AM
Jun-28-24 06:00AM
Jun-11-24 08:00AM
Jun-04-24 08:42AM
May-29-24 07:00AM
07:00AM Loading…
May-28-24 07:00AM
May-15-24 09:52AM
07:00AM
May-10-24 07:00AM
May-08-24 06:45AM
May-06-24 07:28AM
May-01-24 07:31AM
Apr-30-24 04:05PM
Apr-25-24 09:17AM
Apr-24-24 04:05PM
Apr-02-24 10:31AM
Mar-28-24 11:52PM
05:28PM
Feb-21-24 04:05PM
Jan-02-24 07:00AM
02:17PM Loading…
Nov-15-23 02:17PM
Nov-14-23 07:00AM
Nov-08-23 08:12AM
Nov-07-23 07:00AM
Aug-10-23 05:15PM
Aug-03-23 08:00AM
Jul-18-23 08:00AM
Jun-27-23 08:00AM
Jun-20-23 08:00AM
May-23-23 08:30AM
May-15-23 05:15PM
May-08-23 08:00AM
May-02-23 05:10PM
Apr-20-23 05:10PM
Apr-17-23 06:00PM
Apr-04-23 08:30AM
Mar-30-23 08:30AM
Mar-21-23 05:15PM
01:38PM
Mar-17-23 07:00AM
Mar-16-23 05:15PM
Mar-14-23 08:30AM
Mar-09-23 08:30AM
Mar-01-23 07:14AM
Feb-23-23 08:30AM
Feb-21-23 02:04PM
08:30AM
Feb-03-23 08:31AM
Jan-12-23 08:30AM
Dec-13-22 08:30AM
Dec-05-22 08:30AM
Nov-10-22 05:15PM
Oct-25-22 08:30AM
Oct-21-22 02:39PM
Oct-20-22 08:30AM
Sep-19-22 08:30AM
Sep-16-22 05:05PM
Aug-11-22 05:15PM
Aug-09-22 08:00AM
Jul-26-22 08:30AM
May-18-22 05:15PM
May-16-22 08:55AM
May-12-22 05:15PM
Apr-26-22 08:30AM
Mar-31-22 05:25PM
Mar-24-22 08:30AM
Jan-27-22 07:30AM
Jan-13-22 08:30AM
Dec-27-21 05:10PM
Dec-22-21 12:00PM
Dec-21-21 08:30AM
Dec-07-21 08:30AM
Dec-01-21 08:30AM
Nov-10-21 05:15PM
Nov-08-21 03:00PM
Oct-19-21 08:30AM
Sep-15-21 08:30AM
Aug-18-21 01:45PM
Aug-11-21 05:15PM
08:30AM
Aug-05-21 10:39AM
Aug-03-21 08:30AM
Jun-22-21 08:30AM
Jun-18-21 09:30AM
Jun-14-21 09:30AM
Jun-02-21 08:30AM
May-20-21 08:30AM
May-12-21 05:20PM
Apr-27-21 08:30AM
Apr-21-21 08:17AM
Predictive Oncology, Inc. engages in the application of artificial intelligence medicine business and provision of cleared STREAMWAY System for automated, direct-to-drain medical fluid disposal, and associated products. It operates through the following segments: Helomics, zPREDICTA, Skyline, Soluble, and Corporate. The Helomics segment includes contract services that include the application of AI, partnering projects, and clinical testing. The zPREDICTA segment specializes in organ-specific disease models that provide 3D reconstruction of human tissues accurately representing each disease state and mimicking drug response enabling accurate testing of anticancer agents. The Skyline segment is composed of the STREAMWAY System product sales, and its TumorGenesis subsidiary is included within the Corporate segment. The Soluble segment provides services using an automated system that conducts self-interaction chromatography screens, using additives and excipients commonly included in protein formulations resulting in soluble and physically stable formulations for biologics. The company was founded by Lawrence W. Gadbaw, Peter L. Morawetz, and Jeffrey K. Drogue on April 23, 2002 and is headquartered in Pittsburgh, PA.